TCTP is a critical survival factor that protects cancer cells from oxidative stress-induced cell-death

Experimental Cell Research

Volumn 317, Issue 17, 2011, Pages 2479-2489

  Lucibello, Maria ^a   Gambacurta, Alessandra ^b   Zonfrillo, Manuela ^a   Pierimarchi, Pasquale ^a   Serafino, Annalucia ^a   Rasi, Guido ^b   Rubartelli, Anna ^c   Garaci, Enrico ^b  

^a INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Cancer; Stress; Survival

Indexed keywords

ARSENIC TRIOXIDE; BETA ACTIN; GLUCOSE; GLUTATHIONE; HYDROGEN PEROXIDE; PROTEIN TCTP; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CLONE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; UPREGULATION;

EID: 80052629994     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2011.07.012     Document Type: Article

References (53)

1. Gatenby R.A., Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat. Rev. 2004, 4:891-899.
2. DeBerardinis R.J., Lum J.J., Hatzivassiliou G., Thompson C.B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008, 7:11-20.
3. Mathew R., Karantza-Wadsworth V., White E. Role of autophagy in cancer. Nat. Rev. Cancer 2007, 7:961-967.
4. Chen N., Debnath J. Autophagy and tumorigenesis. FEBS Lett. 2010, 584:1427-1435. Review.
5. Dai C., Whitesell L., Rogers A.B., Lindquist S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 2007, 130:1005-1018.
6. Luo J., Solimini N.L., Elledge S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136:823-837.
7. Nitta M., Kozono D., Kennedy R., Stommel J., Ng K., Zinn P.O., Kushwaha D., Kesari S., Furnari F., Hoadley K.A., Chin L., DePinho R.A., Cavenee W.K., D'Andrea A., Chen C.C. Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. PLoS One 2010, 5:e10767.
8. Hoelbl A., Schuster C., Kovacic B., Zhu B., Wickre M., Hoelzl M.A., Fajmann S., Grebien F., Warsch W., Stengl G., Hennighausen L., Poli V., Beug H., Moriggl R., Sexl V. Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol. Med. 2010, 2:98-110.
9. Luo J., Emanuele M.J., Li D., Creighton C.J., Schlabach M.R., Westbrook T.F., Wong K.K., Elledge S.J. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009, 137:835-848.
10. Emadi A., Gore S.D. Arsenic trioxide - an old drug rediscovered. Blood Rev. 2010, 24:191-199.
11. Miller W.H. Molecular targets of arsenic trioxide in malignant cells. Oncologist 2002, 7:14-19. Review.
12. Wang J., Yi J. Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol. Ther. 2008, 7:1875-1884. Review.
13. Brown N.S., Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res. 2001, 3:323-327. Review.
14. Simons A.L., Mattson D.M., Dornfeld K., Spitz D.R. Glucose deprivation-induced metabolic oxidative stress and cancer therapy. J. Cancer Res. Ther. 2009, 5:S2-S6. Review.
15. Grek C.L., Tew K.D. Redox metabolism and malignancy. Curr. Opin. Pharmacol. 2010, 10:362-368. Review.
16. Reuter S., Gupta S.C., Chaturvedi M.M., Aggarwal B.B. Oxidative stress, inflammation, and cancer: how are they linked?. Free Radic. Biol. Med. 2010, 49:1603-1616.
17. R. Venè, P. Castellani, L. Delfino, M. Lucibello, M.R. Ciriolo, A. Rubartelli, The cystine/cysteine cycle and GSH are independent and crucial antioxidant systems in malignant melanoma cells and represent druggable targets, Antioxid. Redox Signal. (in press), doi: [Epub ahead of print]. doi:10.1089/ars.2010.3830.
18. Liu Q., Zhang H., Smeester L., Zou F., Kesic M., Jaspers I., Pi J., Fry R.C. The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel. BMC Med. Genomics 2010, 13:3-37.
19. Ceccarelli J., Delfino L., Zappia E., Castellani P., Borghi M., Ferrini S., Tosetti F., Rubartelli A. The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants. Int. J. Cancer 2008, 123:1770-1778.
20. Filomeni G., Aquilano K., Rotilio G., Ciriolo M.R. Antiapoptotic response to induced GSH depletion: involvement of heat shock proteins and NF-kappaB activation. Antioxid. Redox Signal. 2005, 7:446-455.
21. Lee H.R., Cho J.M., Shin D.H., Yong C.S., Choi H.G., Wakabayashi N., Kwak M.K. Adaptive response to GSH depletion and resistance to l-buthionine-(S, R)-sulfoximine: involvement of Nrf2 activation. Mol. Cell. Biochem. 2008, 318:23-31.
22. Savarino A., Mai A., Norelli S., El Daker S., Valente S., Rotili D., Altucci L., Palamara A.T., Garaci E. "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology 2009, 6:52.
23. Deng S.S., Xing T.Y., Zhou H.Y., Xiong R.H., Lu Y.G., Wen B., Liu S.Q., Yang H.J. Comparative proteome analysis of breast cancer and adjacent normal breast tissues in human. Genomics Proteomics Bioinformatics 2006, 4:165-172.
24. Slaby O., Sobkova K., Svoboda M., Garajova I., Fabian P., Hrstka R., Nenutil R., Sachlova M., Kocakova I., Michalek J., Smerdova T., Knoflickova D., Vyzula R. Significant overexpression of Hsp110 gene during colorectal cancer progression. Oncol. Rep. 2009, 21:1235-1241.
25. Arcuri F., Papa S., Carducci A., Romagnoli R., Liberatori S., Riparbelli M.G., Sanchez J.C., Tosi P., del Vecchio M.T. Translationally controlled tumor protein (TCTP) in the human prostate and prostate cancer cells: expression, distribution, and calcium binding activity. Prostate 2004, 60:130-140.
26. Kim J.E., Koo K.H., Kim Y.H., Sohn J., Park Y.G. Identification of potential lung cancer biomarkers using an in vitro carcinogenesis model. Exp. Mol. Med. 2008, 40:709-720.
27. Chen S.H., Wu P.S., Chou C.H., Yan Y.T., Liu H., Weng S.Y., Yang-Yen H.F. A knockout mouse approach reveals that TCTP functions as an essential factor for cell proliferation and survival in a tissue- or cell type-specific manner. Mol. Biol. Cell 2007, 18:2525-2532.
28. Choi K.W., Hsu Y.C. To cease or to proliferate: new insights into TCTP function from a Drosophila study. Cell Adh. Migr. 2007, 1:129-130. Review.
29. Hsu Y.C., Chern J.J., Cai Y., Liu M., Choi K.W. Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase. Nature 2007, 445:785-788.
30. Yang Y., Yang F., Xiong Z., Yan Y., Wang X., Nishino M., Mirkovic D., Nguyen J., Wang H., Yang X.F. An N-terminal region of translationally controlled tumor protein is required for its antiapoptotic activity. Oncogene 2005, 24:4778-4788.
31. Susini L., Besse S., Duflaut D., Lespagnol A., Beekman C., Fiucci G., Atkinson A.R., Busso D., Poussin P., Marine J.C., Martinou J.C., Cavarelli J., Moras D., Amson R., Telerman A. TCTP protects from apoptotic cell death by antagonizing bax function. Cell Death Differ. 2008, 15:1211-1220.
32. Telerman A., Amson R. The molecular programme of tumour reversion: the steps beyond malignant transformation. Nat. Rev. Cancer 2009, 9:206-216. Review.
33. Graidist P., Yazawa M., Tonganunt M., Nakatomi A., Lin C.C., Chang J.Y., Phongdara A., Fujise K. Fortilin binds Ca2+ and blocks Ca2+-dependent apoptosis in vivo. Biochem. J. 2007, 408:181-191.
34. Bommer U.A., Heng C., Perrin A., Dash P., Lobov S., Elia A., Clemens M.J. Roles of the translationally controlled tumour protein (TCTP) and the double-stranded RNA-dependent protein kinase, PKR, in cellular stress responses. Oncogene 2010, 29:763-773.
35. Berkowitz O., Jost R., Pollmann S., Masle J. Characterization of TCTP, the translationally controlled tumor protein, from Arabidopsis thaliana. Plant Cell 2008, 20:3430-3447.
36. Rehmann H., Brüning M., Berghaus C., Schwarten M., Köhler K., Stocker H., Stoll R., Zwartkruis F.J., Wittinghofer A. Biochemical characterisation of TCTP questions its function as a guanine nucleotide exchange factor for Rheb. FEBS Lett. 2008, 582:3005-3010.
37. Wang X., Fonseca B.D., Tang H., Liu R., Elia A., Clemens M.J., Bommer U.A., Proud C.G. Re-evaluating the roles of proposed modulators of mammalian target of rapamycin complex 1 (mTORC1) signaling. J. Biol. Chem. 2008, 283:30482-30492.
38. Dong X., Yang B., Li Y., Zhong C., Ding J. Molecular basis of the acceleration of the GDP-GTP exchange of human ras homolog enriched in brain by human translationally controlled tumor protein. J. Biol. Chem. 2009, 284:23754-23764.
39. Diraison F., Hayward K., Sanders K.L., Brozzi F., Lajus S., Hancock J., Francis J.E., Ainscow E., Bommer U.A., Molnar E., Avent N.D., Varadi A. Translationally controlled tumour protein (TCTP) is a novel glucose-regulated protein that is important for survival of pancreatic beta cells. Diabetologia 2011, 54:368-379.
40. Han Y.H., Kim S.Z., Kim S.H., Park W.H. Induction of apoptosis in arsenic trioxide-treated lung cancer A549 cells by buthionine sulfoximine. Mol. Cells 2008, 26:158-164.
41. Maeda H., Hori S., Ohizumi H., Segawa T., Kakehi Y., Ogawa O., Kakizuka A. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and l-buthionine-sulfoximine. Cell Death Differ. 2004, 11:737-746.
42. Redmond K.M., Wilson T.R., Johnston P.G., Longley D.B. Resistance mechanisms to cancer chemotherapy. Front. Biosci. 2008, 13:5138-5154. Review.
43. Engelmann A., Speidel D., Bornkamm G.W., Deppert W., Stocking C. Gadd45 beta is a pro-survival factor associated with stress-resistant tumors. Oncogene 2008, 27:1429-1438.
44. Lee A.S. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res. 2007, 67:3496-3499. Review.
45. Gnanasekar M., Ramaswamy K. Translationally controlled tumor protein of Brugia malayi functions as an antioxidant protein. Parasitol. Res. 2007, 101:1533-1540.
46. Nagano-Ito M., Banba A., Ichikawa S. Functional cloning of genes that suppress oxidative stress induced cell death: TCTP prevents hydrogen peroxide-induced cell death. FEBS Lett. 2009, 17:1363-1367.
47. Rid R., Onder K., Trost A., Bauer J., Hintner H., Ritter M., Jakab M., Costa I., Reischl W., Richter K., MacDonald S., Jendrach M., Bereiter-Hahn J., Breitenbach M. H2O2-dependent translocation of TCTP into the nucleus enables its interaction with VDR in human keratinocytes: TCTP as a further module in calcitriol signalling. J. Steroid Biochem. Mol. Biol. 2010, 118:29-40.
48. Ma Q., Geng Y., Xu W., Wu Y., He F., Shu W., Huang M., Du H., Li M. The role of translationally controlled tumor protein in tumor growth and metastasis of colon adenocarcinoma cells. J. Proteome Res. 2010, 9:40-49.
49. Gnanasekar M., Thirugnanam S., Zheng G., Chen A., Ramaswamy K. Gene silencing of translationally controlled tumor protein (TCTP) by siRNA inhibits cell growth and induces apoptosis of human prostate cancer cells. Int. J. Oncol. 2009, 34:1241-1246.
50. Fujii S., Mitsunaga S., Yamazaki M., Hasebe T., Ishii G., Kojima M., Kinoshita T., Ueno T., Esumi H., Ochiai A. Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome. Cancer Sci. 2008, 99:1813-1819.
51. Yoshioka A., Miyata H., Doki Y., Yamasaki M., Sohma I., Gotoh K., Takiguchi S., Fujiwara Y., Uchiyama Y., Monden M. LC3, an autophagosome marker, is highly expressed in gastrointestinal cancers. Int. J. Oncol. 2008, 33:461-468.
52. Fujita T., Felix K., Pinkaew D., Hutadilok-Towatana N., Liu Z., Fujise K. Human fortilin is a molecular target of dihydroartemisinin. FEBS Lett. 2008, 582:1055-1060.
53. Klayman D.L. Qinghaosu (artemisinin): an antimalarial drug from China. Science 1985, 228:1049-1055. Review.